Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19736455 | 0.66 | LMNA (0.42) | LMNAGAAMAPTPOLBMAPK1 | |
| SCHEMBL20095094 | 0.63 | LMNA (0.39) | LMNAGAAMAPTPOLBMAPK1 | |
| SCHEMBL11465347 | 0.61 | ALDH1A1 (0.62) | LMNAGAAPOLBHSD17B10ALDH1A1 | |
| SCHEMBL6368247 | 0.61 | — | — | |
| SCHEMBL8844441 | 0.61 | — | — | |
| SCHEMBL8843999 | 0.59 | POLB (0.50) | LMNAGAAPOLBHTTL3MBTL1 | |
| SCHEMBL31571907 | 0.59 | ALDH1A1 (0.58) | LMNAGAAHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL11500115 | 0.58 | KDM4E (0.41) | LMNAGAAMAPTPOLBHTT | |
| SCHEMBL96698 | 0.57 | — | — | |
| SCHEMBL3237315 | 0.57 | GAA (0.53) | GAAMAPTPOLBHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791119-B1 | N-(1,2,5-OXADIAZOL-3-YL)-, N-(1,3,4-OXADIAZOL-2-YL), N-(TETRAZOL-5-YL)- UND N-(TRIAZOL-5-YL)-ARYL CARBOXYLIC ACID AMIDES AND USE OF SAME AS HERBICIDES | BAYER IP GMBH (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-9204650-B2 | N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)-, and N-(triazol-5-yl) aryl carboxylic acid amides and use thereof as herbicides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20140371068-A1 | N-(1,2,5-OXADIAZOL-3-YL)-, N-(1,3,4-OXADIAZOL-2-YL)-, N-(TETRAZOL-5-YL)-, AND N-(TRIAZOL-5-YL) ARYL CARBOXYLIC ACID AMIDES AND USE THEREOF AS HERBICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | US | disclosed |
| EP-2791119-A1 | N-(1,2,5-OXADIAZOL-3-YL), N-(1,3,4-OXADIAZOL-2-YL), N-(TETRAZOL-5-YL), AND N-(TRIAZOL-5-YL) ARYL CARBOXYLIC ACID AMIDES AND USE THEREOF AS HERBICIDES | Bayer Intellectual Property GmbH (DE) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013087577-A1 | N-(1,2,5-OXADIAZOL-3-YL), N-(1,3,4-OXADIAZOL-2-YL), N-(TETRAZOL-5-YL), AND N-(TRIAZOL-5-YL) ARYL CARBOXYLIC ACID AMIDES AND USE THEREOF AS HERBICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371068-A1 | N-(1,2,5-OXADIAZOL-3-YL)-, N-(1,3,4-OXADIAZOL-2-YL)-, N-(TETRAZOL-5-YL)-, AND N-(TRIAZOL-5-YL) ARYL CARBOXYLIC ACID AMIDES AND USE THEREOF AS HERBICIDES | NAT1, MT-CO3, MT-CO1 | LMNA 3322/4885GAA 1744/4885MAPT 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.